The Trump administration has uncovered a dramatic increase in Medicare claims for tissue and organ transplants, known as allografts, which surged from $200 million in 2019 to $14.4 billion in 2025—a 7,100 percent jump.
This spike prompted the White House Anti-Fraud Task Force, led by Vice President JD Vance, and the Centers for Medicare and Medicaid Services (CMS) to intensify their review of claims. Since March, CMS has denied 96 percent of allograft claims identified during the audit.
CMS Administrator Mehmet Oz reported that the agency identified 4,200 potentially fraudulent allograft claims totaling $224 million through May. “That’s a lot of money,” Oz stated at a recent news conference. “And that bankrupts not just hospital systems and physician groups, but it causes major problems across the entire landscape.”
The administration also announced enforcement actions against Durable Medical Equipment (DME) suppliers, including those providing wheelchairs, walkers, hospital beds, and other medical devices. CMS reported suspending payments to 102 suppliers while revoking billing privileges for another 725 suppliers—their services accounted for 8.6 percent of all Medicare-funded DME in 2025.
CMS officials detailed fraud patterns involving equipment that was not medically necessary, more expensive than prescribed, or never delivered. A spokesperson for Vance’s office declared: “In just six months, the task force has effectively wiped out Durable Medical Equipment fraud in America.”
Oz highlighted the administration’s progress: “Thanks to the whole-of-government approach spearheaded by the White House Anti-Fraud Task Force, we stopped nearly $220 million in fraudulent skin substitute claims and suspended or revoked billing privileges for over 800 DME suppliers.” He warned fraudsters: “Do not walk away from this press conference. Don’t walk away from us. You start running because the vice president and this task force are coming after you.”